Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE D'EVRY VAL D'ESSONNE is currently navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners and 3 distinct art units. BOESEN, CHRISTIAN C is the busiest examiner, holding 1 busiest examiner pending action.
The portfolio shows a broad administrative spread where each of the 3 pending office actions is assigned to a different examiner. Because these actions are in 3 distinct art units, the university must coordinate across three separate departments. The 1 busiest examiner pending action represents 1 of the 3 total pending matters currently active.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOESEN, CHRISTIAN C | 1 | 76.0% | +21.1% |
| CONNORS, ALEXANDRA F | 1 | 23.7% | +45.5% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 92d overdue |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 30d overdue |
| 18013339 | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping | BOESEN, CHRISTIAN C | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| 1634 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18013339 | Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions Swapping | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Dec 28, 2022 |
| 18009006 | Treatment of Genetic Dilated Cardiomyopathies | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | 30d overdue | Pending | Dec 08, 2022 |
| 17625440 | TREATMENT OF GLYCOGEN STORAGE DISEASE (GSD) | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Final Rejection | 92d overdue | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITE D'EVRY VAL D'ESSONNE has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Christian C Boesen has the most, with 1 of UNIVERSITE D'EVRY VAL D'ESSONNE's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
